Published in Infect Immun on October 01, 1996
The continuing challenges of leprosy. Clin Microbiol Rev (2006) 4.09
HLA and infectious diseases. Clin Microbiol Rev (2009) 2.35
Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J Clin Microbiol (2000) 1.85
Use of a whole blood assay to evaluate in vitro T cell responses to new leprosy skin test antigens in leprosy patients and healthy subjects. Clin Exp Immunol (1999) 1.10
Antigenic specificity of the Mycobacterium leprae homologue of ESAT-6. Infect Immun (2002) 1.06
Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy. Immunology (1999) 0.96
Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol (2003) 0.83
Leprosy patients with lepromatous disease recognize cross-reactive T cell epitopes in the Mycobacterium leprae 10-kD antigen. Clin Exp Immunol (1998) 0.81
Dominant recognition of a cross-reactive B-cell epitope in Mycobacterium leprae 10 K antigen by immunoglobulin G1 antibodies across the disease spectrum in leprosy. Immunology (1999) 0.81
Novel 33-kilodalton lipoprotein from Mycobacterium leprae. Infect Immun (2002) 0.81
Setaria digitata adult 14- to 20-kDa antigens induce differential Th1/Th2 cytokine responses in the lymphocytes of endemic normals and asymptomatic microfilariae carriers in bancroftian filariasis. J Clin Immunol (1998) 0.80
Changes in cellular response to mycobacterial antigens and cytokine production patterns in leprosy patients during multiple drug therapy. Immunology (1998) 0.75
Mycobacterium leprae-Infected Macrophages Preferentially Primed Regulatory T Cell Responses and Was Associated with Lepromatous Leprosy. PLoS Negl Trop Dis (2016) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis (1966) 22.28
Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 8.85
Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol (1994) 8.43
CD1-restricted T cell recognition of microbial lipoglycan antigens. Science (1995) 5.03
Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest (1991) 4.08
Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med (1986) 4.05
Human TH1 and TH2 subsets: doubt no more. Immunol Today (1991) 3.81
Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol (1992) 3.03
The etiologic agents of leprosy and tuberculosis share an immunoreactive protein antigen with the vaccine strain Mycobacterium bovis BCG. Infect Immun (1987) 2.66
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains. J Biol Chem (1992) 2.28
Serological activity of a characteristic phenolic glycolipid from Mycobacterium leprae in sera from patients with leprosy and tuberculosis. Clin Exp Immunol (1983) 1.95
A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med (1992) 1.93
Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens. J Infect Dis (1993) 1.63
Positive Mitsuda lepromin reactions in long-term treated lepromatous leprosy. Lepr Rev (1990) 1.44
T-cell recognition of the 18-kilodalton antigen of Mycobacterium leprae. Infect Immun (1989) 1.39
Major structural features of the cell wall arabinogalactans of Mycobacterium, Rhodococcus, and Nocardia spp. Carbohydr Res (1993) 1.32
Characterization of Mycobacterium leprae cell wall-associated proteins with the use of T lymphocyte clones. J Immunol (1989) 1.29
Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol (1992) 1.24
Mycobacterium leprae produces extracellular homologs of the antigen 85 complex. Infect Immun (1992) 1.19
Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide. Proc Natl Acad Sci U S A (1990) 1.18
Effect of multiple interferon gamma injections on the disposal of Mycobacterium leprae. Proc Natl Acad Sci U S A (1989) 1.12
Fibronectin-binding antigen 85 and the 10-kilodalton GroES-related heat shock protein are the predominant TH-1 response inducers in leprosy contacts. Infect Immun (1995) 1.08
Role of Th-1 lymphocytes in the development of protective immunity against Mycobacterium leprae. Analysis of lymphocyte function by polymerase chain reaction detection of cytokine messenger RNA. J Immunol (1992) 1.05
Chemical definition, cloning, and expression of the major protein of the leprosy bacillus. Infect Immun (1994) 0.93
Quantitative antibody ELISA for leprosy. Int J Lepr Other Mycobact Dis (1989) 0.88
The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Lepr Rev (1988) 0.86
Evidence for functional subsets of CD4+ and CD8+ T cells in human disease: lymphokine patterns in leprosy. Chem Immunol (1992) 0.84
Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection. Infect Immun (1992) 0.83
Effect of treatment on immune responsiveness in lepromatous leprosy patients. Lepr Rev (1990) 0.81
Relationship between host histones and armadillo-derived Mycobacterium leprae. Int J Lepr Other Mycobact Dis (1993) 0.81
Cellular immune response to the cell walls of Mycobacterium leprae in leprosy patients and healthy subjects exposed to leprosy. Clin Exp Immunol (1992) 0.80
IgG subclass antibody to Mycobacterium leprae 18,000 MW antigen is restricted to IgG1 and IgG3 in leprosy. Immunology (1994) 0.80
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science (1999) 8.63
Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med (1998) 6.14
A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int J Syst Bacteriol (1997) 5.28
CD1-restricted T cell recognition of microbial lipoglycan antigens. Science (1995) 5.03
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet (2001) 5.01
Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 4.96
Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem (1986) 4.52
Are general practitioners doing enough to promote healthy lifestyle? Findings of the Medical Research Council's general practice research framework study on lifestyle and health. Br Med J (Clin Res Ed) (1987) 4.48
Tropical medicine for the 21st century. BMJ (1995) 4.12
Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol (1990) 3.85
Impact of HIV on tuberculosis in Zambia: a cross sectional study. BMJ (1990) 3.84
Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) (1982) 3.82
Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia. Int J Tuberc Lung Dis (2001) 3.75
Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet (1969) 3.67
Tuberculosis and HIV infection in sub-Saharan Africa. JAMA (1992) 3.51
Immunological evaluation of a component isolated from Mycobacterium bovis BCG with a monoclonal antibody to M. bovis BCG. Infect Immun (1984) 3.46
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut (2005) 3.32
Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med (1994) 3.25
Experimental lepromatous leprosy. Nature (1967) 3.18
Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. J Biol Chem (1982) 3.11
Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis (2002) 3.05
Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol (1992) 3.03
Structural studies on the type-specific antigens and lipids of the mycobacterium avium. Mycobacterium intracellulare. Mycobacterium scrofulaceum serocomplex. Mycobacterium intracellulare serotype 9. J Biol Chem (1979) 3.00
Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol (1999) 2.94
Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr (2000) 2.86
The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A (1996) 2.83
Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis (1999) 2.79
Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet (1992) 2.77
Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun (1991) 2.77
Reversal reactions in leprosy and their management. Lepr Rev (1991) 2.75
A novel phenolic glycolipid from Mycobacterium leprae possibly involved in immunogenicity and pathogenicity. J Bacteriol (1981) 2.70
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature (1984) 2.63
Characterization of the major membrane protein of virulent Mycobacterium tuberculosis. Infect Immun (1992) 2.61
Significance of variations within the lepromatous group. Lepr Rev (1969) 2.59
Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med (1976) 2.45
Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A (2000) 2.44
Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem (2000) 2.43
Can digoxin dose requirements be predicted? Br J Clin Pharmacol (1976) 2.43
Identification of atypical mycobacteria by thin-layer chromatography of their surface antigens. J Clin Microbiol (1978) 2.40
Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis (1993) 2.36
Is there an acute-phase response in steady-state sickle cell disease? Lancet (1993) 2.35
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS (1998) 2.35
Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect Immun (1992) 2.33
Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med (1999) 2.33
Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun (1983) 2.30
Thin-layer chromatography of lipid antigens as a means of identifying nontuberculous mycobacteria. J Clin Microbiol (1982) 2.29
Lipoarabinomannan of Mycobacterium tuberculosis. Capping with mannosyl residues in some strains. J Biol Chem (1992) 2.28
Mycobacterium leprae antigen-induced suppression of T cell proliferation in vitro. J Immunol (1987) 2.27
Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. J Biol Chem (1990) 2.25
The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet (2002) 2.25
Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost (1992) 2.24
Cell-mediated immunity in patients with leprosy. Lancet (1969) 2.21
Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria. J Bacteriol (1980) 2.21
Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun (1988) 2.21
Evidence for the presence of a phosphatidylinositol anchor on the lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. J Biol Chem (1990) 2.20
Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology (1995) 2.19
Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem (1994) 2.18
Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser. Br J Ophthalmol (1977) 2.18
Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother (1995) 2.17
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A (1996) 2.15
Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability. Int Rehabil Med (1979) 2.14
Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol (1998) 2.11
Peptidoglycan-associated polypeptides of Mycobacterium tuberculosis. J Bacteriol (1990) 2.10
Cerebral involvement in benign tertian malaria. Am J Trop Med Hyg (2002) 2.08
Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. Am J Public Health (1993) 2.07
Detection of a mediator derived from endotoxin-stimulated macrohpages that induces the acute phase serum amyloid A response in mice. J Exp Med (1979) 2.03
Phosphatidylinositol is an essential phospholipid of mycobacteria. J Biol Chem (2000) 2.03
Effects of isoniazid on the composition of mycobacteria, with particular reference to soluble carbohydrates and related substances. Biochem J (1967) 2.02
Structures of the glycopeptidolipid antigens from serovars in the Mycobacterium avium/Mycobacterium intracellulare/Mycobacterium scrofulaceum serocomplex. Eur J Biochem (1981) 2.01
Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of Mycobacterium tuberculosis. J Immunol (1989) 2.01
Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi. Br J Ophthalmol (1996) 2.01
Monokine-induced synthesis of serum amyloid A protein by hepatocytes. Nature (1980) 1.97
The major native proteins of the leprosy bacillus. J Biol Chem (1990) 1.96
Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol (2001) 1.96
Evidence for circulating immune complexes in lepromatous leprosy. Lancet (1972) 1.94
A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med (1992) 1.93
Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem (2000) 1.92
Prominence of IgG4 in the IgG antibody response to human filariasis. J Immunol (1985) 1.91
Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest (1978) 1.90
Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med (1993) 1.90
Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. J Clin Microbiol (1990) 1.89
Immunological basis for depression of cellular immunity and the delayed allergic response in patients with lepromatous leprosy. Lancet (1968) 1.88
Human and bovine tuberculosis in the Monze District of Zambia--a cross-sectional study. Br Vet J (1996) 1.88
Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ (2000) 1.87
Evidence for species-specific lipid antigens in Mycobacterium leprae. Int J Lepr Other Mycobact Dis (1980) 1.87
Evidence for glycosylation sites on the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. Infect Immun (1995) 1.86
Theory and method in the quantitative analysis of "impulsive choice" behaviour: implications for psychopharmacology. Psychopharmacology (Berl) (1999) 1.85
Remedial therapy after stroke: a randomised controlled trial. Br Med J (Clin Res Ed) (1981) 1.84
Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J Bacteriol (1996) 1.83
Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res Microbiol (1991) 1.82
A DNA methylation imprint, determined by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. Genomics (1992) 1.82